Table 3 List of p-tau specific immunotherapy drugs currently in clinical development
Drug Name | Mechanism | Phase | Clinical Trial ID | Population | Status |
|---|---|---|---|---|---|
JNJ-63733657 | Antibody against pThr217 | Phase I | NCT03375697 | Healthy Adults | Completed |
Phase I | NCT03689153 | AD, Healthy Adults | Completed | ||
Phase II | NCT04619420 | AD | In Progress until 2025 | ||
PNT001 | Antibody against Cis isomer of pThr231 | Phase I | NCT04677829 | Patients with Traumatic Brain Injury | In Progress until 2022 |
Phase I | NCT04096287 | Healthy Adults | In Progress until 2021 | ||
Lu AF87908 | Antibody against pSer396 | Phase I | NCT04149860 | AD | In Progress until 2021 |
RO6926496 | Antibody against pSer404 | Phase I | NCT02281786 | Healthy Adults | Completed |
ACI-35 | Vaccine of tau peptide with pSer396/pSer404 | Phase I/II | NCT04445831 | AD | In Progress until 2023 |